D-Phenylalanine (DPA, D-Phe), sold under the brand names Deprenon, Sabiben, and Sabiden, is an enantiomer of phenylalanine which is described as an antidepressant and is marketed as a prescription drug for medical use in Argentina.[1][2] The medication has been marketed since at least the 1970s[3] and continued to be available by the 2000s.[1]
Clinical data | |
---|---|
Trade names | Deprenon, Sabiben, Sabiden |
Other names | D-( )-Phenylalanine; (R)-( )-Phenylalanine; (R)-Phenylalanine; D-β-Phenylalanine; DPA; D-Phe |
Routes of administration | By mouth |
Drug class | Antidepressants; Enkephalinase inhibitors |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.010.549 |
Chemical and physical data | |
Formula | C9H11NO2 |
Molar mass | 165.192 g·mol−1 |
3D model (JSmol) | |
| |
|
D-Phenylalanine has been found to act as an enkephalinase inhibitor, an inhibitor of enkephalinase enzymes that break down endogenous opioid peptides called enkephalins.[4][5] It has been found to produce anti-inflammatory, analgesic, and anti-craving effects in animal studies.[4][6][7][8]
See also
editReferences
edit- ^ a b Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 825. ISBN 978-3-88763-075-1. Retrieved 23 July 2024.
- ^ Negwer, M. (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. p. 323. ISBN 978-3-05-500156-7. Retrieved 23 July 2024.
D-Phenylalanine (●) D-α-Amino-β-phenylpropionic acid = (R)-α-Aminobenzenepropanoic acid S Deprenon "Promeco", D-Phenylalanine, Sabiden U Antidepressant
- ^ Unlisted Drugs. Unlisted Drugs Committee of the Pharmaceutical Section, Science-Technology Group, Special Libraries Association. 1979. Retrieved 23 July 2024.
- ^ a b Millinger GS (April 1986). "Neutral amino acid therapy for the management of chronic pain". Cranio. 4 (2): 157–163. doi:10.1080/08869634.1986.11678141. PMID 3519793.
- ^ Thanawala V, Kadam VJ, Ghosh R (October 2008). "Enkephalinase inhibitors: potential agents for the management of pain". Curr Drug Targets. 9 (10): 887–894. doi:10.2174/138945008785909356. PMID 18855623.
- ^ Trachtenberg MC, Blum K (1987). "Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol". Am J Drug Alcohol Abuse. 13 (3): 365–372. doi:10.3109/00952998709001520. PMID 2825513.
- ^ Blum K, Baron D, McLaughlin T, Gold MS (April 2020). "Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS)". J Neurol Sci. 411: 116733. doi:10.1016/j.jns.2020.116733. PMID 32088516.
- ^ Blum K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Demetrovics Z (2016). "Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity". Curr Pharm Des. 22 (38): 5837–5854. doi:10.2174/1381612822666160719111346. PMID 27510492.